Background Use of oral snuff or 'snus' has risen in Sweden. Sales of snuff in the US have also risen, overtaking sales of chewing tobacco. There is some evidence that nicotine contributes to circulatory disease (CID) from smoking. We therefore reviewed the evidence relating smokeless tobacco (ST) to CID and related risk factors.
Introduction
Smokeless tobacco (ST) is mainly used orally, and nasal use has become rare. [1] [2] [3] The two major products used in North America and Europe are chewing tobacco and snuff. There are several types of chewing tobacco and snuff, differing in their formulation and how the tobacco is treated. In the United States, ST has formed an important part of total tobacco consumption for many years, e.g. 11.2% of all tobacco products by weight in 1950, 9.6% in 1980 and 12.9% in 2000. 4 For many years sales of chewing tobacco were two or three times those of snuff, but since the early 1980s sales of snuff have risen sharply and have recently overtaken sales of chewing tobacco. 4 Partly this may be because some types of fine-cut ST classified as chewing tobacco prior to 1981 are now categorized as moist/fine-cut snuff. 1 In most other economically developed countries, ST forms only an unimportant part of the tobacco market. 4 Though ST forms a few per cent of the market in Canada, Iceland and Norway, the most notable exception is Sweden where snuff ('snus') has always formed a large proportion of total sales of tobacco by weight (70% in 1920, 31% in 1950, 29% in 1980, 53% in 2000), though sales of chewing tobacco there are negligible. As in the US, the use of snuff in Sweden has increased sharply in recent decades.
ST is also widely used in parts of Central and South-East Asia. Use occurs in various ways, with the tobacco used alone or in combination with other products, such as betel nut quid, slaked lime, areca nut and even snail shells. [1] [2] [3] Studies conducted in Sweden [5] [6] [7] [8] [9] [10] [11] [12] and the US [13] [14] [15] [16] [17] and also in the UK 18 provide evidence that the use of snuff and chewing tobacco involves an exposure to nicotine that is fairly equivalent to that from cigarette smoking. Indeed some of the studies in Sweden 5-10 reported higher plasma cotinine levels in users of snuff. Since nicotine has been implicated in several processes related to cardiovascular disease, 19 the possibility that ST, like cigarette smoking, might result in an increased risk, therefore deserves consideration. In this context, however, it should be noted that pipe smoking, which also results in nicotine exposure similar to that from cigarette smoking, is associated with an increase in heart disease risk that is substantially lower than that for cigarette smoking. 20, 21 This review is concerned with evidence relating ST use to circulatory disease (CID). Attention is restricted to chewing tobacco and snuff, with no consideration of the limited data on nicotine chewing gum. Attention is also restricted to studies in Western populations (in practice this means US and Sweden), omitting studies in Central and South-East Asia where, as noted above, products used are variable and often involve the inclusion of non-tobacco material.
The review concentrates on evidence from epidemiological studies linking use of ST to mortality from or onset or prevalence of ischaemic heart disease (IHD), acute myocardial infarction (AMI), stroke, or all CID. A briefer summary is also given of evidence linking use of ST to risk factors for heart disease such as diabetes, hypertension, cholesterol, fibrinogen, platelet function and ultrasonographic measurements of atherosclerosis.
An earlier review by Critchley and Unal 22 which concluded that 'there may be an association between ST use and cardiovascular disease' was limited, partly because it did not include meta-analyses, partly because studies of stroke were not included and partly because it only included three [23] [24] [25] of the eight epidemiological studies now available on IHD or AMI. Four were published in 2005 [26] [27] [28] and one earlier. 29 
Methods
In December 2005, publications describing results of epidemiological case-control, cohort and cross-sectional studies relating ST use to risk of CID were sought from our in-house files, supplemented by a MEDLINE search (using the terms smokeless tobacco and cardiovascular disease) and from reference lists of articles retrieved. Publications relating to risk factors relevant to CID were similarly sought, with clinical studies also considered. From the studies of CID risk, details were extracted of the study design, location and timing and of the potential confounding variables considered. Where available, estimates of the relative risk (RR) or odds ratio (OR) associated with ST use were extracted together with their associated 95% confidence interval (CI). The RRs and ORs extracted related to AMI (international classification of diseases (ICD) 9th revision 410), IHD (ICD 410-414, equivalent to coronary heart disease), stroke ICD 430-438 ¼ cerebrovascular disease], all CID (390-459 ¼ cardiovascular disease), or other CID. Attention was limited to estimates where the groups being compared differed only in exposure to ST use and not in exposure to smoking. Thus, if for example the source article presented RRs for each combination of ST use (ever, never) and smoking (current, former, never) relative to a totally unexposed denominator (never ST, never smoking), the RRs were recalculated, using standard methods, [30] [31] [32] to compare ever and never ST users separately for current, former and never smokers. Fixed-effects meta-analysis 33 would then be used to combine these estimates to produce a smoking-adjusted overall RR estimate. Fixed-effects meta-analysis was also used to combine RRs reported separately by age. Where RRs for a given comparison were available with varying degrees of confounder adjustment that adjusted for the most variables was selected for analysis. In order to obtain an overall estimate of the risk associated with ST use, RR and OR estimates were combined by metaanalysis. 33 Since an OR is an approximation to an RR, the combined estimate is referred to as being a RR estimate. Results are presented in the tables for both fixed-effects and randomeffects models, with the random-effects estimates being cited in the text where appropriate. The studies of risk factors related to CID were reviewed in a less detailed manner, mainly to summarize the number of studies which did and did not report associations of ST use with the various endpoints considered.
Results

CID
The studies Table 1 Bolinder et al. 23 Johansson et al. 27 Accortt et al. 29 Henley et al. 26 Henley et al. Table 3 ). f Analyses of CID excluded men who reported prevalent heart disease, diabetes or stroke at baseline, while analyses of IHD excluded men who reported prevalent heart disease or diabetes at baseline and analyses of stroke excluded men who reported prevalent stroke at baseline. g Questions were not asked about past ST use, but some men volunteered answers. h Years are approximate, as described by the authors. i Questions on ST use were only asked of a sample in 1971-75, but were asked of everyone in a follow-up survey in 1982-84. Individuals reporting current ST use in 1971-75 or ever use in 1982-84 were considered ever users of ST. j For both chewing tobacco and snuff, regular ¼ at least once a week for at least a year. k Bolinder et al. 34 also presents results from this survey based on cross-sectional analysis of the 1971-74 sample relating ST use to risk of disability retirement due to CID. l Further adjustment for blood pressure, body mass index, diabetes and history of heart symptoms or blood pressure medication had little effect. m Further adjustment for socio-economic status had no effect. n Cholesterol and body mass index not adjusted for in analyses of stroke.
analyses of CPS-I and CPS-II, 35 with the analyses of the Swedish construction workers study 23 excluding those who had used pipes or cigars and those with mixed use of ST and cigarettes. All of the cohort studies took a range of potential confounding variables into account, though in one study 23 detailed analyses were only presented adjusted for age and region, it being noted that additional adjustments had little effect on the risk estimates. Table 2 similarly summarizes details of the five case-control studies that have been carried out, all in Sweden. 24, 25, 28, 36, 37 Four of the five studies were conducted in the two northernmost counties, Norrbotten and Västerbotten. Two of these 24, 25 were non-overlapping case-control studies of AMI, while the other two 36 (i) In females in the First NHANES follow-up study 29 there was little evidence that ST increased risk of death from all CID (hazard ratio 1.2, 95% CI 0.7-1.9 in never smokers) after adjustment for age, race and poverty, or that ST increased risk of IHD (1.4, 0.8-2.2 in never smokers; 1.1, 0.4-3.2 in ever smokers) or stroke (1.0, 0.3-2.9 in never smokers; 1.7, 0.4-7.0 in ever smokers) after adjustment for a longer list of potential confounding variables (Table 1) ; (ii) In males and females combined in the first MONICA/VIP study 36 the crude OR for stroke was not increased (0.56, 95% CI 0. 25-1.27 ).
This evidence is clearly too sparse to allow a reliable conclusion, so, in the following, attention is restricted to males. Table 3 presents RR or OR estimates relating to various indices of ST use, smoking groups and vascular endpoints. The first estimate listed is an OR deriving from a cross-sectional study 34 which formed the baseline of a cohort study, 23 Table 4 presents the results of various meta-analyses based on the estimates in Table 3 . The first three of these are presented as forest plots in Figure 1 . For IHD or AMI, the eight RR/OR estimates for current ST use among never smokers (or the nearest equivalent available) showed some heterogeneity ( 2 ¼ 13.11 on 7 df, P ¼ 0.07), varying from 0.60 to 1.41. The random-effects estimate was not clearly increased overall (1.12, 95% CI 0.99-1.27), or when results were considered separately for the US (1.14, 0.96-1.34) or Sweden (1.06, 0.83-1.37). Excluding estimate 9, which was for ever rather than current use, the random-effects estimate for Sweden and US combined changed slightly to 1.15 (1.03-1.29). Estimates were increased for cohort studies but not for case-control studies (heterogeneity 2 ¼ 4.58 on 1 df,
Meta-analyses
Although the combined estimates in Table 4 provide some indication of a weak association of IHD or AMI with current ST use in never smokers, they provided no indication of any increase in risk associated with current ST use in current smokers or in all individuals, or of any increase in risk associated with former ST use. For stroke, the five estimates for current ST use among never smokers showed no heterogeneity For all CID, the three estimates for current ST use among never smokers showed no marked heterogeneity ( 2 ¼ 4.58 on 2 df, P ¼ 0.10), and the random-effects estimate was increased (1.25, 1.13-1.37). The analyses of risk associated with current ST use in never smokers were heavily dependent on the contributions of the two large US CPS studies. Thus, for IHD or AMI, CPS-I provided 62.3% and CPS-II 17.0% of the total weight of the combined estimate. Corresponding percentages were 76.3% and 16.2% for stroke and 68.2% and 18.5% for all CID, respectively. Excluding CPS-I and CPS-II the random-effects estimates showed little evidence of an association for IHD or AMI (0.99, 0.76-1.30) or for stroke (1.11, 0.78-1.59).
Risk by age
Although there is clear evidence that the association of smoking with IHD is age-dependent, with an increasing RR with decreasing age, only two of the 10 studies presented RRs or ORs for ST by age. In the Swedish construction workers study, 23 the risk of IHD associated with current ST use in never smokers was higher (P ¼ 0.02) in men aged 35-54 at entry into the study (RR 2.0, 95% CI 1.4-2.9) than in men aged 55-65 at entry (RR 1.2, 95% CI 1.0-1.5). In contrast, in the first MONICA study, 24 the risk of AMI was somewhat lower Huhtasaari et al. 24 Huhtasaari et al. 25 Hergens et al. 28 Ahmed et al.
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Dose response
Only two studies presented any dose-response results for ST use. In CPS-II, 26 frequency and duration of use among current ST users was unrelated to risk of IHD, stroke or all CID, despite there being over 200 cases of CID in ST users. In the first MONICA study, 24 users of 2þ cans of snuff a day had no increased risk of AMI, though power to detect a dose-response was limited.
Separate associations with chewing tobacco and snuff
In CPS-II, 26 RRs for IHD, stroke and all CID did not differ notably between those who chewed tobacco and never used snuff and those who used snuff and never chewed. However, the number of deaths in the second category was relatively low. Figure 1 Forest plot of selected random-effect meta-analyses shown in Table 4 : data from Sweden and the US; current ST use (or near equivalent) in never smokers (or near equivalent) workers study, 23 or AMI associated with current (or ever) ST use separately for never (or non-current) smokers and for current smokers. As shown in Table 5 , the smoker/non-smoker ratio of these estimates was close to 1 and provided no indication of a multiplicative interaction between the effects of smoking and the possible effects of ST. Thus, the data did not indicate any special hazard in relation to the dual use of smoking and ST. No effect of snuff use or smoking was seen on fasting glucose levels in three studies 9, 10, 45 or on glucose levels during a euglycaemic clamp in another study. 42 One study 10 reported no effect of snuff or smoking on post-load glucose levels in men, but did observe some decrease with smoking in women.
Effect of smoking
Other outcomes
Diabetes
The clamp study 42 reported that basal glucose utilization was reduced by smoking but unaffected by snuff use. The evidence relating to insulin levels following fasting is unclear. Evidence of increases relating to snuff and smoking was seen in two studies. 9, 45 In contrast, no increase was seen in an experimental study 42 or in either sex in another study. 10 Indeed, women who smoked had a clearly lower fasting insulin than non-users in that study, which also reported somewhat lower post-load insulin levels in male snuff users and smokers of either sex. Insulin levels during a euglycaemic clamp were unaffected by snuff use or smoking. 42 In an experimental study 42 smoking, but not snuff use, was found to impair insulin action, mainly due to a lower peripheral glucose uptake. A cross-sectional study 44 found that, in men with impaired glucose tolerance, the odds of a low insulin response were increased in smokers and in former but not current snuff users. No such association was seen in individuals with normal glucose tolerance.
Blood pressure
In the US, nine experimental studies, 13,14,50-56 mainly of crossover design, consistently reported an acute rise in blood pressure following use of ST. They also consistently reported an acute rise in heart rate. The studies 13, 14 comparing acute effects of smoking with ST found them to be similar in respect of effects on heart rate and blood pressure. An acute rise in blood pressure following ST use has also been noted in some case reports emanating from the US. [57] [58] [59] [60] Some authors 14,60-62 have suggested that sodium or liquorice in ST may contribute to the blood pressure increase, though a direct effect of nicotine is more commonly referred to. Two studies, 55, 56 in which the controls were given, as a placebo, snuffs that did not contain tobacco and were nicotine-free, observed no acute rise in blood pressure.
In Sweden, only one experimental study, 63 of crossover design, has investigated acute effects of oral snuff. Clear rises in blood pressure and heart rate were seen during rest, but not during exercise. Smoking was not investigated in this study.
A number of cross-sectional studies have been carried out comparing blood pressure in ST users and non-users. Six such studies have been conducted in the US 29, 50, [64] [65] [66] [67] and nine in Sweden. [8] [9] [10] 12, 27, 28, 34, 45, 68 Four of the six US studies 29, 50, 64, 65 provided evidence of an increased blood pressure in ST users. However, in two of these studies, 29, 65 no age adjustment was carried out despite the ST users being markedly older than the non-tobacco users, and in one 64 the increase related only to men aged 18 to 25, with no results reported for older men, or for women. Only one of the nine studies in Sweden 34 reported increased blood pressure in ST users. This was the study of construction workers, noted earlier to have reported an association with cardiovascular mortality and incidence of MI.
Other use to a range of other CID-related endpoints.
The material from the US included two case reports of Buerger's disease associated with the use of chewing tobacco, 69, 70 one study which reported that smoking but not ST was associated with reduced exercise performance, 71 one study which reported an increased plasma lactate concentration and decreased stroke volume associated with ST use 73 and one study 56 which reported that snuff use was associated with an increase in mean arterial pressure and epinephrine, but not peripheral vascular resistance, muscle sympathetic nerve activity or norepinephrine. Two studies reported results relating to lipid levels. One of these studies 72 reported that risk of hypercholesterolaemia was increased in both smokers and ST users. The RR in ST users implausibly increased from 1.08 to 2.51 after adjustment for potential confounding factors. A second study 66 found no notable association of ST use with total cholesterol or HDL cholesterol levels, but did find some evidence of a reduction in HDL levels with increasing serum cotinine. One US study 29 reported a number of differences (including lower blood cholesterol and higher dietary fat intake) between exclusive ST users and those who had never used tobacco. However, these analyses, though based on a large sample, were not adjusted even for age and sex.
The studies in Sweden concerned a range of endpoints, but the results generally showed a consistent picture. Apart from two reports 34, 74 of a similar increase in prevalence of Raynaudtype symptoms in both ST users and smokers, a report of an increase in triglycerides 45 in ST users that was less marked than that seen in smokers, and a report 28 that current snuff users were more likely to be overweight, the studies all showed little evidence of an adverse effect of ST use for endpoints that are virtually all associated with smoking. This conclusion applies to endpoints such as atherosclerosis, 7, 45 response to exercise, 6, 12 cholesterol levels, 7, 9, 28, 45, 68 triglycerides, 7,9,68 fibrinogen, 7, 9, 10, 68 markers of platelet activity 12 and levels of antioxidant vitamins. 75 Exceptionally, one study 10 reported no effects of either ST use or smoking on cholesterol levels and triglycerides.
Discussion
This review was carried out to investigate in detail the epidemiological and clinical evidence relating CID and risk factors for CID to use of ST in Western populations. Since the use of ST, whether in the US or Sweden, involves an exposure to nicotine that is quite comparable with that from cigarette smoking, since cigarette smoking is associated with an increased risk of CID, and since nicotine has been implicated in several processes related to the disease, there is concern that the use of ST also might increase risk. Although, in view of the much lower heart disease risk in pipe smokers, such concern might not be fully justified, it was decided to review the available evidence relevant to this concern.
CID
Based on 10 epidemiological studies of mortality or disease onset (Tables 1 and 2 ), three conducted in the US and seven in Sweden, meta-analyses have been conducted based on the results for men, the available data for women being extremely limited. Among never smokers, the combined evidence (Table 4) gave some indication of a weak association of IHD or AMI with current ST use in never smokers, but no indication of any increase in risk in current smokers or with former ST use. The associations with stroke and with all CID among never smokers were somewhat more clearly seen. The analyses have a number of strengths. These include quite a substantial total number of cases in the meta-analyses, availability of estimates adjusted for a wide range of relevant potential confounding variables in the majority of the studies and long-term follow-up in all the cohort studies. Limitations include variations in the definitions of exposure and of disease endpoints between study, small numbers of individuals and lack of confounder control in a few studies, the fact that five of the seven Swedish studies were conducted in the same area of Sweden and particularly the lack of good recent data from the US.
The appropriateness of carrying out meta-analysis at all deserves some comment. While recognizing that there is an active discussion about the use of meta-analysis to pool data from observational studies, 76 and that the uncertainty about the meta-analytic estimates may not be fully expressed by the conventional statistical indices, failure to combine estimates might have produced conclusions that are more uncertain than the data warrant. The meta-analyses were conducted by combining RRs from cohort studies and ORs from case-control studies. ORs somewhat overestimate RRs where, as here, the disease is not rare, 77 but the overestimation is of little practical importance for ORs in the range considered 78 (e.g. for a disease with an incidence of 10% an OR of 1.20 is equivalent to an RR of 1.18) and has been ignored. The first meta-analysis shown in Table 4 combines results for fatal and non-fatal AMI. In theory, effects of ST may differ for the two types, but in practice only two of the studies investigated this possibility. The two counties' study 28 reported that such analysis did not change its conclusion of a lack of increased risk of AMI from ST, while though the second MONICA study 25 More data are needed here. Although the clearest way to evaluate possible effects of ST is to compare risks in current (and former) users who have never smoked with those who have never used tobacco, the limited data on risks of ST use in smokers or in the whole population (with adjustment for smoking) have also been considered. Given the large effect of smoking and the scope for imprecise classification, there are inevitably uncertainties about smokingadjusted risks, but joint use of ST and smoking is very far from uncommon and it is important to gain some insight into whether it involves unexpected risks. In fact, the data provided no evidence of an association of ST use with increased risk of IHD or AMI in current smokers or in all individuals. Although the apparent lack of effect of ST use in smokers, taken together with the evidence of a possible effect in never smokers, might at first suggest the existence of some interaction of ST and smoking on risk, in fact, formal analysis (Table 5) did not confirm this.
Evidence of an association of current ST use with risk was only apparent in three studies, the two US CPS studies for IHD, stroke and all CID and the Swedish construction workers study for IHD and all CID (Table 3) . When attempting to interpret the data it is important to note that, of those seven studies which found no evidence of an increased risk of IHD or AMI associated with ST use, none reported any results for all CID and only two did so for stroke.
The overall evidence is dependent particularly on the two CPS studies, which together provide 76% of the total studied cases of IHD or AMI and 90% of those of stroke. Although these studies are large, of cohort design and adjust for quite a wide range of confounding variables, a number of their features require comment. First, the questions on ST use were asked in 1959 (CPS-I) and 1982 (CPS-II), and it is unclear how relevant the products used at that time are to the ST currently on the market. Second, the question used in CPS-I-'Do you chew tobacco or use snuff?' with answers recorded as 'Never,' 'Occasionally' or 'Regularly'-made no specific provision for former use, though those respondents who happened to volunteer such information were excluded from analysis. Third, all the multivariate-adjusted estimates shown in Table 3 were lower than the age-adjusted estimates given by Henley et al. 26 reflecting the generally poorer lifestyle characteristics of ST users than non-tobacco users, and bringing into question the possibility of some residual confounding. Finally, Table 5 of Henley et al. 26 showed, based on over 200
cases of cardiovascular disease in ST users in CPS-II, that there was no indication of a dose-response relationship with IHD, stroke or all CID, such a relationship usually being considered a prerequisite for demonstrating causality. Evidence on doseresponse from other studies was extremely limited, and more information is clearly needed here. The meta-analyses provide no clear evidence from studies in Sweden of an association of current ST use with IHD or AMI or with stroke. While there is no significant heterogeneity by country, and the evidence, particularly for stroke, is quite limited, the data are consistent with Swedish snus having little or no true effect on risk of CID. Given the ST products used in Sweden and in the US have historically been very different, there is no compelling reason to expect any effects of ST to be the same in the two countries.
Although the analyses are mainly concerned with quantifying risks for ST use in comparison with no ST use, comparisons were also made with risks associated with smoking. In both Sweden and the USA, risks for IHD/AMI, stroke and all CID were always clearly higher in relation to smoking than in relation to ST.
One of the problems in obtaining reliable evidence on the risk of CID associated with ST as currently used is the lack of recent data, particularly in the US, where the nature of the product has changed over time, 79 and the only three epidemiological studies providing information are cohort studies where the baseline information was collected 25 years or more ago (Table 1 ). There is a need for a substantial case-control study of CID to be conducted in the US (and perhaps also in Sweden) which would obtain detailed data on use of ST, smoking history and potential confounding factors.
Other outcomes
The approach taken here was to review the evidence qualitatively. Because of limitations in how the data were reported, useful meta-analyses could not practically be carried out. For the risk factors associated with CIDs, which have been discussed in this report, there is little clear evidence of any effect of snuff as used in Sweden. One study reported an association with diabetes, 44 but other studies in Sweden did not (Table 6) , and no effect on insulin levels or on glucose levels or uptake has been consistently reported. In Sweden, blood pressure levels have generally been found to be similar in snuff users and non-users, though one experimental study 63 reported an acute rise in blood pressure at rest from oral snuff, a finding which needs replication. Use of snuff has been repeatedly reported in Swedish studies to have no evident effect on a variety of other endpoints, including atherosclerosis, response to exercise, cholesterol levels, triglycerides and fibrinogen. However, there have been two reports of an increase in prevalence of Raynaud-type symptoms in snuff users. 34, 74 While it is possible that larger and better designed studies in Sweden may detect other circulatory effects of snuff, it seems clear for many risk factors that if there is an effect it is less than that of smoking. As used in the US, ST does have effects on risk factors relevant to CID. The most commonly reported is an acute rise of blood pressure and heart rate, seen in many experimental studies. There may also be a chronic effect on blood pressure, though some of the cross-sectional studies reporting an increase suffer from evident weaknesses. Whether cross-sectional studies can be regarded as providing evidence on chronic effects, as suggested by Westman, 62 seems dubious, because while people are unlikely to be using ST while their blood pressure is being taken, it seems eminently possible that, unless instructions have been given to the contrary, some people may have been using it very recently, when its acute effects are still occurring. While four of the nine cross-sectional studies conducted in Sweden appear to have attempted to avoid acute effects, by insisting on abstention from tobacco overnight, 9 for at least 8 h, 8 for an hour 10 or in the waiting room 34 ,
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Downloaded from https://academic.oup.com/ije/article-abstract/36/4/789/665480 by guest on 25 November 2018 none of the six US studies reported that it did so. No notable effect on diabetes mortality was seen in the CPS-I and CPS-II studies. 26 There are also two case reports of Buerger's disease associated with the use of chewing tobacco 69, 70 and isolated reports of a variety of endpoints relative to CID. As for mortality or disease onset, the findings for ST as used in the US are more suggestive of a possible effect on the circulatory system than is the case for the findings for snuff as used in Sweden.
Conclusion
The overall evidence on use of snuff taken from a substantial number of studies in Sweden does not demonstrate any increase in the risk of CID, any chronic effect on blood pressure or any increased risk of a range of other risk factors relevant to CID. More evidence is needed to confirm whether Swedish oral snuff causes an acute rise in blood pressure. It may increase risk of Raynaud-type symptoms. The evidence of a possible effect of ST as used in the US is more compelling. Two large cohort studies have reported finding evidence of an increased risk of IHD and stroke, with the increase substantially less than seen in smokers. However, these studies have limitations and were conducted many years ago, and more up-to-date evidence is needed. An acute effect of ST on blood pressure and heart rate is well documented, but a chronic effect has not been clearly shown. The evidence on circulatory risk factors is difficult to generalize, but shows more associations with ST than seen in the Swedish studies.
Risk of CID associated with ST use is clearly substantially less than that associated with smoking and it has in fact not been clearly demonstrated that Swedish oral snuff is associated with any adverse effect at all in either non-smokers or smokers. However, the number of studies available is still limited and more evidence is needed.
Although smokers who wish to reduce their risk of CID would clearly do best to reduce their risk of CID by giving up smoking, many find great difficulty in doing so and may find that switching to ST is easier. The evidence suggests strongly that switching would indeed substantially reduce their risk, though studies which compared risks of those who switched and those who continued to smoke would be needed to confirm this.
CID is clearly only one of the possible consequences of ST use, and reliable data are needed on a variety of other endpoints before any overall judgement can be made as to its health effects in non-smokers and the benefits of switching to smokers.
[Subsequent to our searches, the INTERHEART case-control study of tobacco use and risk of AMI conducted in 52 countries reported that chewing tobacco alone was associated with an OR of 2.23 (1.41-3.52), but numbers of snuff users were too small to draw conclusions. However, since the majority of ST users in this study were from South Asia, with no separate results reported for Western populations, these findings do not affect our conclusions.]
